SanegeneBio has formed a research and licensing partnership with Eli Lilly and Company to develop RNAi candidates for ...

From 18-20 November, Formulated Solutions will be attending the Florida Innovation Conference, held by BioFlorida, at the Walt Disney ...

Though the FDA has requested no new data, the additional information reflects a major amendment to Rhythm’s supplemental new ...

Approval of J&J's Darzalex marks a milestone for high-risk sMM patients, but GlobalData analyst Biswajit Podder believes ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Abzena and Mabqi have announced a partnership integrating antibody discovery capabilities with development and manufacturing ...

Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the MHRA for all four formulations of ...

Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.